Presentations from Top Biopharma 


Supporting Therapeutic Protein Discovery at the Discovery/Development Interface
John E. Harlan, PhD, Senior Group Leader, AbbVie Inc.


Characterization of Challenging Proteins and Protein Complexes Using Native and Denaturing Mass Spectrometry
Dhanashri Bagal, Senior Scientist, Discovery Attribute Sciences, Amgen, Inc.

CHO Cell Engineering to Improve Therapeutic Antibody Production
Cai Guo, PhD, Scientist, Mammalian Expression & Biologics Optimization, Amgen Inc.

Supporting Therapeutic Protein Discovery at the Discovery/Development Interface
John E. Harlan, PhD, Senior Group Leader, AbbVie Inc.

KEYNOTE PRESENTATION: Lessons Learned from Expression Liabilities in a Four-Chain Bispecific
Rene Hubert, PhD, Director, Biologics Optimization, Amgen Inc.

High Molecular Weight Species in Therapeutic Monoclonal Antibody Products: Physicochemical Characterization and Analysis of Impact on Drug Safety and Efficacy
Nathan Joh, PhD, Senior Scientist, Team Lead, Amgen, Inc.

KEYNOTE PRESENTATION: Advances in High-Throughput Protein Purification at Different Scales
John K. Kawooya, PhD, Director, Biologics Optimization and Therapeutic Discovery, Amgen Inc.

Membrane Mimetics to Facilitate Antibody Screening
Christy A. Thomson, PhD, Senior Scientist, Amgen, Inc.

Accelerating Higher-Throughput Discovery Workflows with Informatics Advances and Next-Gen Predictive Tools
Daniel Yoo, Senior Scientist, Therapeutic Discovery, Amgen Inc.


Novel CHO Host for Improved Recombinant Protein Production
Lina Chakrabarti, PhD, Senior Manager, R&D, AstraZeneca

Increasing the Dynamic Binding Capacity of Hydrophobic Interaction Chromatography (HIC) Resins Using a Dual Salt System
Dhanesh Gadre, Scientist I, Purification Process Sciences, AstraZeneca

Efficient Humanization of Mouse mAbs Facilitated by Functional Screening
Maria Groves, PhD, Director and Head of the Antibody Alliance Laboratory, AstraZeneca, United Kingdom

Design Meets Biology – Engineering a PD-1/CTLA-4 Monovalent Bispecific Antibody to Improve Both Safety and Efficacy
Yariv Mazor, PhD, Principal Scientist, Antibody Discovery & Protein Engineering, AstraZeneca

Qualitative Analysis of Protein Aggregates in Biotherapeutics by Backgrounded Membrane Imaging (BMI)
Markela Murphy, Dosage Form Design & Development, Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, US


Testing and Improving Antibody Developability during Candidate Discovery and Optimization
Mark C. Julian, PhD, Scientist I, Biologics Drug Discovery, Biogen

Adeno-Associated Virus (AAV) Genome Integrity Analysis by Capillary Gel Electrophoresis
Yi Pu, PhD, Scientist II, Analytical Development, Biogen

Boehringer Ingelheim Pharmaceuticals

Optimization of a Transient Antibody Expression Platform towards High Titer and Efficiency
Elizabeth A. Greene, Scientist IV, Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc.

Modeling Approaches in High-Throughput System
Vignesh Rajamanickam, Boehringer Ingelheim

Eli Lilly & Co.

The Use of a High-Throughput, One-Step Transient-to-Stable Cell Line Generation Process for Accelerated Delivery of Proteins in Early Discovery
Marina Alvi, PhD, Senior Research Scientist, Mammalian Protein Expression, Eli Lilly & Co.

Discovery and Development of SARS-CoV-2 Neutralizing Antibody LY-CoV555
Bryan E. Jones, PhD, Research Fellow, BioTechnology Discovery Research, Eli Lilly & Co.

F. Hoffmann-La Roche AG

Discovery and Development of Faricimab, a CrossMab Antibody Targeting Both Vascular Endothelial Growth Factor (VEGF-A) and Angiopoietin (Ang)-2, for the Treatment of Retinal Diseases
Christoph Ullmer, PhD, Senior Principal Scientist, pRED Discovery Ophthalmology, F. Hoffmann-La Roche AG


Building Higher-Throughput Multi-Host Automated Mid-Scale Protein Purification and Screening Platform for Research
Kanika Bajaj Pahuja, PhD, Scientific Manager, Protein Sciences, Genentech Inc.

Deep Learning Approaches for Neoantigen Prediction
Kai Liu, PhD, Principal AI Scientist, Head, Medical Language Processing, Early Clinical Development, Genentech, Inc.

Merging Antibody and Small Molecule Drug Discovery: CLAMPs to Study and Drug Dynamic Proteins
James T. Koerber, PhD, Principal Scientist, Antibody Engineering, Genentech, Inc.

Apoptosis-Resistant CHO Cell Lines Significantly Improve Culture Viability and Titer in Intensified Fed-Batch Culture Process
Shahram Misaghi, PhD, Principal Scientist, Cell Culture and Bioprocess Operations (CCBO), Genentech, Inc.

Development of Antibody-Based PROTACs
Thomas Pillow, PhD, Senior Scientist, Genentech, Inc.

Extended Characterization and Impact of Visible Fatty Acid Particles – A Case Study with a mAb Product
Anthony Tomlinson, Technical Development Scientist, Pharmaceutical Development, Genentech, Inc.

Molecular Interaction Characterization Strategies for the Development of New Antibody Modalities to Enable IND Filing
Xiangdan Wang, PhD, Principal Scientist, BioAnalytical Sciences, Genentech, Inc.


Accelerating Antibody Discovery with in silico Repertoire Screening and Rational Design
Bryan Wu, PhD, NGS Lead, GlaxoSmithKline Biopharm Discovery, United Kingdom

Janssen Pharmaceuticals

Considerations for Plasmid DNA Used in Cell Therapy Manufacturing
Basak Clements, PhD, Associate Director, Material Science, Janssen Pharmaceuticals, Inc.

Structural Mass Spectrometry as Investigational Tool in Early Biotherapeutics Development
Harsha Gunawardena, PhD, Senior Scientist, Mass Spectrometry, Janssen Pharmaceutical Companies of Johnson & Johnson

Challenges and Opportunities in Cell Therapy Formulation and Delivery
Bharathi Vellalore, PhD, Scientist, Biotherapeutics Drug Product Development, Janssen


KEYNOTE PRESENTATION: Cell Engineering Efficiency and Quality
Zhimei Du, PhD, Director, Biologics & Cell Therapeutics Process Development, Merck and Co., Inc., United States

In vitro Screening Tools for the Selection of Membrane-Permeable Peptides
Iriny Ekladious, PhD, Senior Scientist, Sterile & Specialty Products, Merck

Predicting Antibody Developability Profiles through Early Stage Discovery Screening
Laurence Fayadat-Dilman, PhD, Senior Director, Protein Sciences, Merck Research Labs

Understanding the Structural Basis to Design Lipid Nanoparticle (LNP) Formulations
Yongchao Su, PhD, Principal Scientist, Analytical Research and Development, Merck & Co.

Efficient NK Cell Redirection by Triggering NKp30
Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA


Characterization of CARs from the Cell Surface Combining Immunoprecipitation and Mass Spectrometry to Look at Post-Translational Modifications
Jenifer Kaplan, PhD, Principal Scientist I, Novartis Institutes for Biomedical Research


Rapid Discovery and Development of Common Light Chain Bispecific Antibodies with Unique Mechanisms of Action
Pawel K. Dominik, PhD, Principal Scientist, BioMedicine Design, Pfizer

Prediction of Amino Acid Consumption in Chinese Hamster Ovary Cell Fed-Batch Cultures by Coupling a Genome-Scale Metabolic Network Model with Machine Learning
Wei Wei, PhD, Principal Scientist, Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc.


Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Prostate Cancer
Dimitris Skokos, PhD, Senior Director, Cancer Immunology, Regeneron Pharmaceuticals


From Data to Predictions: Computational Optimization of Multi-Specific Protein Therapeutics
Norbert Furtmann, PhD, Section Head, Data Science & Computational Design, Large Molecule Research, Sanofi, Germany

Developability of Complex Multispecifics
Sagar V. Kathuria, PhD, Senior Principal Scientist, Large Molecule Research, Sanofi

Adaptation of a CHO Perfusion Platform to HEK293 & the Impact on Select Product Quality Attributes
Gabriel Lurz, PhD, Research Engineer, Sanofi

Multispecific Therapeutic Antibodies: Using Intact Mass Characterization to Guide Strategic Decisions in Early-Stage Research
Kalie A. Mix, PhD, Senior Scientist, Large Molecule Research, Sanofi Genzyme R&D Center

Systematic Approach to Evaluating Closed System Transfer Devices (CSTDs) During Drug Product Process Development
Sanket Patke, PhD, Associate Director, Sanofi

Ultra-Dilute Solution Measurements of Antibody Self-Association
Charles G. Starr, PhD, Scientist, Developability & Preformulation Sciences, Sanofi Group

KEYNOTE PRESENTATION: Trispecific Antibodies – Taking the Concept of Multi-Targeting One Step Further
Ercole Rao, PhD, Group Leader Biologics Research, Engineered Protein Therapeutics, Sanofi Germany GmbH

Fc Engineering for Site-Specific Antibody Conjugation through Engineered Double Cysteine Residues
Qun Zhou, PhD, Project Head, Large Molecules Research, Innovation US, Sanofi

Takeda Pharmaceuticals

Systematic and Deep Characterization of Host Cell Proteins (HCPs)
Michael Dolan, Staff Engineer, Process Development US, Takeda Pharmaceuticals